Benefits
Less gas and bloating after a meal high in raffinose-family sugars (beans, legumes, cruciferous vegetables)
Three small randomized trials point the same way, with limits worth knowing. In 19 adults fed meatless chili in a crossover design, 8 drops of enzyme cut flatulence events per hour versus placebo (P = .016), while bloating and pain did not differ (Ganiats 1994). In 8 healthy volunteers fed 420 g of cooked beans, 1,200 GalU lowered breath hydrogen and flatulence severity, and both 300 and 1,200 GalU lowered the total symptom score (Di Stefano 2007). In a parallel-group trial in 52 children aged 4 to 17 with chronic or recurrent gas symptoms, two weeks of enzyme reduced global distress, days of moderate to severe bloating and the proportion reporting flatulence, with no change in abdominal spasms or distension (Di Nardo 2013). Every one of these trials is small and short.
Narrow scope: works on galacto-oligosaccharides only, not the rest of the FODMAP family
The enzyme only breaks down the galacto-oligosaccharide branch of the FODMAP family (raffinose, stachyose, verbascose). It does not touch lactose, the fructans in wheat and onion, excess fructose, or the polyols sorbitol and mannitol, so it is not a general low-FODMAP solution. Within its own lane the picture is mixed. In 31 IBS patients fed high-GOS, low-other-FODMAP foods, 300 GalU cut overall symptoms and bloating among the 21 who actually reacted to GOS, though breath hydrogen did not differ from placebo (Tuck 2018). Against that, in 125 IBS patients who took the enzyme with meals for 12 weeks the fall in symptom severity was only a non-significant trend and quality of life did not differ from placebo (Hillila 2016), and 20 IBS patients given 1,200 GalU with high-oligosaccharide meals showed no difference from placebo in symptoms, breath hydrogen or methane (Bohn 2021). Treat it as a way to handle one specific bean or legume meal, not as a treatment for IBS.
Timing and dose are what make it work
The enzyme has to be in the gut at the same time as the food, so every trial gave it at the start of the meal; it does not help with gas from a meal already eaten. Dose matters too. In healthy volunteers, 1,200 GalU lowered breath hydrogen and flatulence severity while 300 GalU moved only the total symptom score (Di Stefano 2007), and in GOS-sensitive IBS patients the full 300 GalU dose reduced symptoms while the 150 GalU half dose did not reach significance (Tuck 2018). Products sold as multi-enzyme digestive blends contain alpha-galactosidase alongside several other enzymes, and any result from such a blend cannot be credited to this enzyme on its own.
Mechanism of action
Hydrolysis of α-1,6 galactosyl bonds in raffinose-family oligosaccharides
Alpha-galactosidase cleaves the α-1,6 glycosidic bond connecting galactose to other sugars in raffinose (galactose-glucose-fructose), stachyose (galactose-galactose-glucose-fructose), and verbascose (galactose-galactose-galactose-glucose-fructose). Humans lack endogenous alpha-galactosidase enzymes capable of digesting these compounds — they pass to the colon where Bacteroides and Bifidobacterium species ferment them, producing CO2, hydrogen, and methane gases.
Acid stability and small intestine activity
Aspergillus niger-derived alpha-galactosidase is acid-stable (active at pH 3–7) and can begin working in the stomach and continue throughout the small intestine. This provides a broader window of activity compared to pH-sensitive enzymes that only work at neutral pH.
Substrate-specific — minimal effect on other dietary components
Unlike broad-spectrum digestive enzyme blends, alpha-galactosidase is highly substrate-specific. It targets only the raffinose-family oligosaccharides without affecting protein, fat, starch, or other carbohydrate digestion. It leaves most medications alone, with one documented exception: taken with the type 2 diabetes drug acarbose it blunts that drug's glucose-lowering effect.
Clinical trials
Double-blind crossover trial in 19 subjects fed test meals of meatless chili. Each subject received either alpha-galactosidase (8 drops) or placebo at first test meal, then crossed over after 1 week. Symptoms recorded for 6 hours post-meal. (Ganiats et al. 1994, Journal of Family Practice)
19 subjects with self-reported high-fiber diet intolerance. Crossover.
Flatulence events per hour were significantly lower with alpha-galactosidase than with placebo across the 6 hours (P = .016), although when the hourly intervals were compared one by one the difference reached significance only at hour 5. Bloating and pain did not differ between the two arms. Authors concluded oral alpha-galactosidase solution is efficacious, at least in some patients, for prophylaxis of gastrointestinal intolerance of oligosaccharides. Beano was already an over-the-counter product before this trial ran.
Randomized, double-blind, placebo-controlled trial in 8 healthy volunteers ingesting 420 g of cooked beans (containing 7.56 g galacto-oligosaccharides) with 300 GalU, 1200 GalU, or placebo of alpha-galactosidase. Breath hydrogen and symptoms (bloating, abdominal pain, flatulence, discomfort, diarrhea) measured for 8 hours. (Di Stefano et al. 2007, Digestive Diseases and Sciences)
8 healthy volunteers. Randomized acute meal challenge.
Both 300 and 1200 GalU doses significantly reduced total symptom score vs placebo. Only the higher 1200 GalU dose significantly reduced breath hydrogen excretion and flatulence severity. Suggests dose-response: higher doses more effective for objective gas reduction, but even 300 GalU helps subjective symptoms.
Randomized, double-blind, placebo-controlled, cross-over trial in IBS patients (Rome III criteria, hydrogen-producers). Three arms: full-dose (300 GalU), half-dose (150 GalU), or placebo enzyme co-ingested with high-GOS, low-other-FODMAP foods for 3 days each, with washout periods. (Tuck et al. 2018, American Journal of Gastroenterology)
31 adults meeting Rome III criteria for IBS who were hydrogen producers on breath testing; 21 of them proved GOS-sensitive and only those 21 are in the efficacy result. Crossover.
31 IBS patients completed the study; adding high-GOS foods raised symptoms in 21 of them. In those 21, full-dose 300 GalU reduced overall symptoms (median 5.5 mm on enzyme vs 24.5 mm on placebo, 100 mm scale, P = 0.006) and bloating (6.5 vs 20.5, P = 0.017). Breath hydrogen production was minimal and did not differ between placebo and full dose (P = 0.597). The half-dose 150 GalU arm did not reach significance. Authors concluded alpha-galactosidase can be used as adjunct to a low-FODMAP diet for IBS patients sensitive to galacto-oligosaccharides.